Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07423494 · ClinicalTrials.gov registry record · Phase 1
Personalized Antisense Oligonucleotide Therapy for A Single Patient With CHCHD10 ALS (nL18576)
A Phase 1 study, sponsored by n-Lorem Foundation.
- Not yet
- Registry status
- Phase 1
- Development phase
- 1
- Enrollment target
NCT07423494 is a Phase 1 study that has not yet begun recruiting, run by n-Lorem Foundation. The registered enrollment target is 1 participants.
The verdict
NCT07423494, a Phase 1 study, has not yet begun recruiting, sponsored by n-Lorem Foundation.
- NOT YET RECRUITING
- Registry status
- Phase 1
- Development phase
- 1 participants
- Enrollment target
Study Summary
This research project entails delivery of a personalized antisense oligonucleotide (ASO) drug designed for a single participant with amyotrophic lateral sclerosis (ALS) due to a pathogenic variant in CHCHD10
Interventions
- DRUG nL-CHCHD-001
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2026-03 |
| Est. Completion | 2027-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07423494
The ClinicalTrials.gov registry entry for NCT07423494 describes a study currently listed as not yet recruiting, categorized as Phase 1. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is n-Lorem Foundation, which has 12 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which nL-CHCHD-001 is the first listed.
NCT07423494 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07423494 about?
NCT07423494 is a clinical study titled "Personalized Antisense Oligonucleotide Therapy for A Single Patient With CHCHD10 ALS (nL18576)". This research project entails delivery of a personalized antisense oligonucleotide (ASO) drug designed for a single participant with amyotrophic lateral sclerosis (ALS) due to a pathogenic variant in CHCHD10
What is the current status of trial NCT07423494?
This trial is currently not yet recruiting. It is a Phase 1 study. The enrollment target is 1 participants. The study started on 2026-03. Estimated completion is 2027-03.
What interventions are being tested in trial NCT07423494?
The interventions under investigation include: nL-CHCHD-001 (DRUG).
Who is sponsoring clinical trial NCT07423494?
This trial is sponsored by n-Lorem Foundation, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.